Inhibrx Biosciences (INBX) Operating Income (2023 - 2025)
Historic Operating Income for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.8 million.
- Inhibrx Biosciences' Operating Income rose 2774.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 5834.88%. This contributed to the annual value of -$331.4 million for FY2024, which is 5119.35% down from last year.
- Per Inhibrx Biosciences' latest filing, its Operating Income stood at -$33.8 million for Q3 2025, which was up 2774.75% from -$27.4 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Operating Income registered a high of -$27.4 million during Q2 2025, and its lowest value of -$160.9 million during Q2 2024.
- Moreover, its 3-year median value for Operating Income was -$46.3 million (2023), whereas its average is -$61.1 million.
- In the last 5 years, Inhibrx Biosciences' Operating Income crashed by 28921.6% in 2024 and then soared by 8297.74% in 2025.
- Over the past 3 years, Inhibrx Biosciences' Operating Income (Quarter) stood at -$88.3 million in 2023, then soared by 43.45% to -$49.9 million in 2024, then soared by 32.28% to -$33.8 million in 2025.
- Its Operating Income was -$33.8 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$42.9 million in Q1 2025.